Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cytokinetics (CYTK) Shares Outstanding (Weighted Average): 2009-2025

Historic Shares Outstanding (Weighted Average) for Cytokinetics (CYTK) over the last 17 years, with Sep 2025 value amounting to $119.7 million.

  • Cytokinetics' Shares Outstanding (Weighted Average) rose 1.70% to $119.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $119.7 million, marking a year-over-year increase of 1.70%. This contributed to the annual value of $118.0 million for FY2024, which is 20.36% up from last year.
  • As of Q3 2025, Cytokinetics' Shares Outstanding (Weighted Average) stood at $119.7 million, which was up 0.19% from $119.4 million recorded in Q2 2025.
  • In the past 5 years, Cytokinetics' Shares Outstanding (Weighted Average) registered a high of $119.7 million during Q3 2025, and its lowest value of $71.1 million during Q1 2021.
  • In the last 3 years, Cytokinetics' Shares Outstanding (Weighted Average) had a median value of $104.9 million in 2024 and averaged $107.8 million.
  • Data for Cytokinetics' Shares Outstanding (Weighted Average) shows a peak YoY rose of 22.56% (in 2024) over the last 5 years.
  • Cytokinetics' Shares Outstanding (Weighted Average) (Quarterly) stood at $83.9 million in 2021, then climbed by 12.81% to $94.6 million in 2022, then increased by 3.62% to $98.1 million in 2023, then rose by 20.36% to $118.0 million in 2024, then increased by 1.70% to $119.7 million in 2025.
  • Its last three reported values are $119.7 million in Q3 2025, $119.4 million for Q2 2025, and $118.4 million during Q1 2025.